Showing 1461-1470 of 2656 results for "".
- Bausch’s Papa Says ‘Transformation on Track’ as Debt Paydown Continueshttps://modernod.com/news/bauschs-papa-says-transformation-on-track-as-debt-paydown-continues/2479690/The turnaround at Quebec-based Bausch Health Cos. appeared to take another step forward Tuesday, after the company reported positive organic growth for the third quarter, sending shares up more than five percent in Toronto, according to a Financial Post
- The Vision Council Concludes Virtual Annual Business Meetinghttps://modernod.com/news/the-vision-council-concludes-virtual-annual-business-meeting/2480592/The Vision Council hosted its annual Business Meeting in a virtual format January 24. Presented under the banner of “It’s All Connected,” the meeting included a welcome address from Karen Roberts, The Vision Council’s Chair, followed by remarks from Ashley Mil
- Moderna’s COVID-19 Vaccine Shows Sustained Protection at Six Monthshttps://modernod.com/news/modernas-covid-19-vaccine-shows-sustained-protection-at-six-months/2479079/Moderna announced longer-term data Tuesday from the phase 3 trial used to support authorizations of its coronavirus vaccine mRNA-1272, saying the vaccine continues to show more than 90% efficacy against cases of COVID-19, including 95% protection from severe disease, a median 6 months after the s
- Biden to Sign Orders to Establish 3-Month ACA Sign-Up Period, Roll Back Trump’s Medicaid Prioritieshttps://modernod.com/news/biden-to-sign-orders-to-establish-3-month-aca-sign-up-period-roll-back-trumps-medicaid-priorities/2478811/President Joe Biden is expected to sign an executive order Thursday that sets up a special enrollment period for the Affordable Care Act’s (ACA’s) insurance exchanges to run from Feb. 15 to May 15, according to a FierceHealthcare
- Wize Pharma Announces Positive Topline Results in Phase 4 Study of LO2A for Dry Eye in Patients with Sjögren’s Syndromehttps://modernod.com/news/wize-pharma-announces-positive-topline-results-in-phase-4-study-of-lo2a-for-dry-eye-in-patients-with-sjogrens-syndrome/2478529/Wize Pharma reported topline results from its phase 4 clinical trial of its in-license eye drop formula, LO2A, for the symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren’s syndrome. The randomized, double-masked comparative study evaluated LO2A versus Alcon̵
- Novo Nordisk’s Rybelsus Gains FDA Approval as First Oral GLP-1 Receptor Agonist for Type 2 Diabeteshttps://modernod.com/news/novo-nordisks-rybelsus-gains-fda-approval-as-first-oral-glp-1-receptor-agonist-for-type-2-diabetes/2476907/The FDA announced Friday the approval of Novo Nordisk’s Rybelsus (semaglutide) to improve control of blood glucose in adults with type 2 diabetes, along with diet and exercise, making it the first oral GLP-1 receptor agonist cleared in the US. Lisa Yanoff, acting director of the Division of
- Kriya Therapeutics Appoints Theresa Heah, MD, as Chief Medical Officer and President of Kriya Ophthalmologyhttps://modernod.com/news/kriya-therapeutics-appoints-theresa-heah-md-as-chief-medical-officer-and-president-of-kriya-ophthalmology/2480354/Kriya Therapeutics announced the appointment of Theresa Heah, MD, MBA, as Chief Medical Officer and President of Kriya’s newly launched ophthalmology division, Kriya Ophthalmology. Dr Heah will be responsible for advancing Kriya’s current pipeline of ophthalmology gene therapies and c
- Ceyeber Announces Advisory Board of World-Renowned Ophthalmologistshttps://modernod.com/news/ceyeber-announces-advisory-board-of-world-renowned-ophthalmologists/2479167/Ceyeber, the developer of implantable intraocular lens technology designed for medical applications and augmented reality, has created a Medical Advisory Board consisting of top ophthalmologists. Ceyeber’s founder and CEO, Robert E. Grant, said, “
- Ace Vision Group Appoints Cristos Ifantides, MD, as Director, Clinical Applications Developmenthttps://modernod.com/news/ace-vision-group-appoints-cristos-ifantides-md-as-director-clinical-applications-development/2481436/Ace Vision Group (AVG) announced the appointment of Cristos Ifantides, MD, MBA, as Director, Clinical Applications Development, effective immediately. In his new role, Dr. Ifantides will lead the education and clinical adoption efforts of AVG's forthcoming presbyopia technology
- Amydis Receives NIH Grant to Develop a Novel Tau Retinal Tracer for Alzheimer’s Diseases and Other Tauopathieshttps://modernod.com/news/amydis-receives-nih-grant-award-to-develop-a-novel-tau-retinal-tracer-for-alzheimers-diseases-and-other-tauopathies/2479481/Amydis announced a new phase 1 grant award from the National Institute of Aging at the National Institutes of Health (NIH) to support the development of a novel small-molecule retinal tracer targeting the biomarker tau for the detection and diagnosis of Alzheimer’s disease and other tauopathies.<